Name: RODRIGO ALVES FARIA
Publication date: 13/07/2022
Advisor:
Name |
Role |
|---|---|
| SONIA ALVES GOUVEA | Advisor * |
Examining board:
| Name |
Role |
|---|---|
| ADRIANA MADEIRA ALVARES DA SILVA | External Examiner * |
| LÍVIA CARLA DE MELO RODRIGUES | Internal Examiner * |
| PATRICK WANDER ENDLICH | External Examiner * |
| SONIA ALVES GOUVEA | Advisor * |
Summary: Breast cancer is the most incident and the fifth in mortality worldwide, with a heterogeneous character, its spread involves a succession of clinical and pathological stages. There is an association between breast cancer and cardiovascular damage, recognized as a poor prognosis regardless of age, for this reason, the clinical approach using new tools that makes it possible to investigate the anticipated inflammatory profile, as well as improve the screening approach aimed at early diagnosis, are essential and necessary strategies, therefore, our aim was to investigate the inflammatory profile in women with breast cancer and apply FTIR spectroscopy as a screening method. We included 90 patients with an initial diagnosis of breast cancer. Clinical-epidemiological data were obtained together with blood collection before therapy. The present study showed that the increased levels of cytokines TNF-α, INF-γ, Il-2, IL-6, IL-17A, IL-4 and IL-10 by flow cytometry in the cancer, tumor size, Axillary lymph nodes and distant metastasis are associated with low overall survival and worse prognosis, as well as being more susceptible to the pathogenesis of several CVD's. Regarding FTIR spectroscopy, the method distinguished cancer and control samples by supervised analysis (PLS-DA). The main variance was found in the band 1511 cm-1 in the control group, 1502 and 1515 cm-1 in the cancer group. The spectral peaks responsible for the identification of breast cancer were attributed to proteins and amide II. Its spectral biomarker performed the distinction by plasma obtaining 97% sensitivity, 93% specificity, 97% ROC curve and 94% prediction. In light of the above, we suggest the clinical application of the cytokines evaluated as a primary phase biomarker in women newly diagnosed with breast cancer, regardless of demographic variables and tumor size, before undergoing any oncological treatment, due to their potential as a predictor of cardiovascular dysfunction and prognostic evaluation, as well as, we propose FTIR spectroscopy as a tool to aid in breast cancer screening.
